Associations Between Sex, Disease Features and Outcome in Patients With Acute Myeloid Leukemia: A Sex‐Stratified Analysis of the GIMEMA AML1310 Trial

Documenti analoghi

• A GIMEMA survey on therapeutic use and response rates of FLT3 inhibitors in acute myeloid leukemia: Insights from Italian real‐world practice
  di: Monica Messina, et al.
  Pubblicazione: (2024)
• Unlocking the potential of synthetic patients for accelerating clinical trials: Results of the first GIMEMA experience on acute myeloid leukemia patients
  di: Alfonso Piciocchi, et al.
  Pubblicazione: (2024)
• APL‐like subset within NPM1 ‐mutated AML: A distinct immunophenotype correlating with early vascular complications
  di: Francesco Mannelli, et al.
  Pubblicazione: (2026)
• Outcome of Chronic Myeloid Leukemia Patients Not in Deep Molecular Response: Results From the GIMEMA LabNet CML Network Database
  di: Fabio Stagno, et al.
  Pubblicazione: (2025)
• Similar efficacy outcomes with peripheral blood stem cell versus bone marrow for autologous stem cell transplantation in acute myeloid leukemia: Long‐term follow‐up of the EORTC‐GIMEMA randomized AML‐10 trial
  di: Frédéric Baron, et al.
  Pubblicazione: (2024)